Revenue Growth
LifeVantage reported third quarter revenues of $58.4 million, marking a 21% increase year-over-year. U.S. revenues grew 31% year-over-year, driven by strong demand for the MindBody GLP1 system.
Profitability Improvements
Adjusted EBITDA increased 27% year-over-year to $6.4 million, with an adjusted EBITDA margin improvement of 50 basis points to 11%. Gross margin also improved by 210 basis points to 81%.
Active Accounts and Subscriptions
Active accounts increased by 17% in the Americas, with a 13% increase in independent consultants and a 19% increase in customers. Subscription orders showed strong growth, with global active templates increasing by over 10,000.
International Expansion
LifeVantage began the international expansion of the MindBody system in Japan, Australia, New Zealand, Mexico, the UK, Europe, and Thailand, with momentum building in these markets.
Successful Product Launch
The launch of the MindBody GLP1 system in the U.S. in October 2024 has been a success with significant sales growth. The product is also being introduced in international markets with promising initial results.
Positive Clinical Study Results
A clinical study revealed that the MindBody GLP1 system increased GLP1 levels in the body by over 200% on average, validating its effectiveness.